Breaking News Instant updates and real-time market news.

SRPT

Sarepta

$61.74

-0.61 (-0.98%)

, ANTM

Anthem

$122.44

0.09 (0.07%)

10:39
10/07/16
10/07
10:39
10/07/16
10:39

Sarepta down after Anthem says Exondys 51 not medically necessary

Sarepta (SRPT) shares are moving lower after Anthem (ANTM) in a Medical Policy statement on its website said that the company's Duchenne muscular dystrophy treatment Exondys 51 is "not medically necessary." Anthem stated, "The use of eteplirsen is considered investigational and not medically necessary for all indications, including but not limited to the treatment of Duchenne muscular dystrophy." Shares of Sarepta are down 3%, or $2.05, to $59.69 in early trading. A parent of a child with DMD yesterday tweeted that Humana (HUM) is going to cover 100% of the cost of Exondys 51 for her child. Reference Link

SRPT

Sarepta

$61.74

-0.61 (-0.98%)

ANTM

Anthem

$122.44

0.09 (0.07%)

HUM

Humana

$176.75

-0.48 (-0.27%)

  • 02

    Nov

  • 06

    Nov

SRPT Sarepta
$61.74

-0.61 (-0.98%)

10/05/16
ADAM
10/05/16
NO CHANGE
Target $28
ADAM
Buy
Summit Therapeutics price target raised to $28 from $14 at Canaccord
Canaccord analyst Arinda Lee raised her price target on Summit Therapeutics (SMMT) to $28 from $14 following the announcement of its collaboration and licensing agreement with Sarepta Therapeutics (SRPT). The deal calls for Sarepta to gain EU commercialization rights to Summit's pipeline of oral utrophin modulators for all patients with Duchenne muscular dystrophy. Lee reiterated her Buy rating Summit Therapeutics shares.
10/04/16
PIPR
10/04/16
NO CHANGE
Target $68
PIPR
Overweight
Piper Jaffray ups Sarepta target to $68 on Summit deal
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics (SRPT) to $68 from $64 after the company licensed Summit Therapeutics' (SMMT) ezutromid to treat Duchenne Muscular Dystrophy in Europe, Turkey and the Commonwealth of Independent States. The deal is a smart way for Sarepta to capitalize on its lead in DMD with the recent FDA approval of Exondys51, Tenthoff tells investors in an intraday research note. His new price target of $68 reflects the value of ezutromid. Tenthoff reiterates an Overweight rating on Sarepta. The stock is up 1% to $61.61 in late morning trading. Summit is up 94%, or $8.17, to $16.82.
09/28/16
JMPS
09/28/16
NO CHANGE
JMPS
Street underestimating price of Sarepta drug, says JMP Securities
JMP Securities analyst Liisa Bayko expects the price of Sarepta's Exondys 51 drug will be above the company's projected annual net price of $300,000. She thinks that the price will come in "closer to $538,000 per year on a gross basis, $457,000 net of discounts and compliance." The analyst raised her price target on the shares to $90 from $60 and keeps an Outperform rating on the stock.
09/28/16
09/28/16
NO CHANGE

Experts 'fairly upbeat' on Sarepta drug, says RBC Capital
After speaking with three neurologists who treat DMD, RBC Capital analyst Simos Simeonidis says that the doctors were "fairly bullish" on Sarepta's DMD treatment, EXONDYS 51. The doctors expect to use the drug "in essentially all eligible patients," according to the analyst. Simeonidis raised the price target on Sarepta to $108 from $83 and keeps an Outperform rating on the stock.
ANTM Anthem
$122.44

0.09 (0.07%)

09/20/16
BOFA
09/20/16
NO CHANGE
BOFA
Anthem removed from US 1 List at BofA/Merrill
09/13/16
JEFF
09/13/16
DOWNGRADE
Target $138
JEFF
Hold
Anthem downgraded to Hold from Buy at Jefferies
Jefferies analyst David Windley downgraded Anthem (ANTM) to Hold from Buy saying the restoration of some of the company's expense cuts could limit 2017 earnings growth. "The belt-tightening also potentially signals under-investment in the platform," Windley tells investors in a research note. He sees a lack of catalysts for Anthem shares and cut his price target to $138 from $156. The health benefit company closed yesterday up $1.63 to $128.58. In Managed Care, Windley's top pick is UnitedHealth (UNH). The company has an attractive valuation and "best-in-class" management team, Windley argues. He has a Buy rating on UnitedHealth with a $163 price target.
08/25/16
COWN
08/25/16
NO CHANGE
COWN
Managed Care mergers unlikely to close, says Cowen
Cowen analyst Christine Arnold believes the current managed care mergers including Aetna (AET) and Humana (HUM) and Anthem (ANTM) and Cigna (CI) are unlikely to close. The analyst said the government's ability to appeal could extend the litigation process beyond the termination dates stipulated in the merger agreements. Arnold believes the Aetna/Humana merger has a better chance of closing relative to the Anthem/Cigna deal, but believes neither are likely to close.
09/22/16
EVER
09/22/16
INITIATION
Target $133
EVER
Hold
Anthem initiated with a Hold at Evercore ISI
Evercore ISI initiated Anthem with a Hold and a $133 price target.
HUM Humana
$176.75

-0.48 (-0.27%)

09/22/16
EVER
09/22/16
INITIATION
EVER
Buy
Humana initiated with a Buy at Evercore ISI
07/22/16
COWN
07/22/16
NO CHANGE
Target $160
COWN
Outperform
Cigna has greatest upside should DOJ block mergers, says Cowen
Cowen noted the DOJ tone toward the pending managed care deals is decidedly negative and raised the burden of proof on the companies to demonstrate the deals are not anti-competitive. Cowen believes Cigna has the most upside of the four companies involved whether the deals go through or not. Cowen has an Outperform rating and $160 price target on Cigna shares.
08/22/16
LEER
08/22/16
NO CHANGE
LEER
Leerink less positive that Anthem challenge to DOJ lawsuit will be successful
Following a conference call with an anti-trust specialist, Leerink analyst Ana Gupte is less positive that the Anthem (ANTM) challenge to the lawsuit by the DOJ will be successful. The analyst says that the specialist views the obstacles to a defense by Anthem-Cigna (CI) to the anti-trust concerns as too numerous to result in a successful close. Further, the analyst believes that any favorable decision, however unlikely, on the merger close, will likely be appealed by the DOJ. Nonetheless, the lower likelihood of this defense being successful may improve the odds of a successful Aetna (AET)-Humana (HUM) defense, the analyst notes.

TODAY'S FREE FLY STORIES

WYNN

Wynn Resorts

$118.22

2.65 (2.29%)

16:15
04/25/17
04/25
16:15
04/25/17
16:15
Hot Stocks
Breaking Hot Stocks news story on Wynn Resorts »

Wynn Resorts sees Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

EW

Edwards Lifesciences

$98.91

0.95 (0.97%)

16:15
04/25/17
04/25
16:15
04/25/17
16:15
Earnings
Edwards Lifesciences reports Q1 adjusted EPS 94c, consensus 82c »

Reports Q1 revenue $884M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WYNN

Wynn Resorts

$118.22

2.65 (2.29%)

16:15
04/25/17
04/25
16:15
04/25/17
16:15
Hot Stocks
Wynn Resorts reports Q1 Las Vegas revenue up 6% to $412.9M »

Reports Q1 Las Vegas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MTSI

MACOM

$53.84

-0.17 (-0.31%)

16:15
04/25/17
04/25
16:15
04/25/17
16:15
Earnings
MACOM sees Q3 adjusted EPS 67c-71c, consensus 69c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

O

Realty Income

$59.81

-0.27 (-0.45%)

16:14
04/25/17
04/25
16:14
04/25/17
16:14
Earnings
Realty Income reports Q1 EPS 27c, consensus 29c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 16

    May

MRCY

Mercury Systems

$38.38

-1.35 (-3.40%)

16:14
04/25/17
04/25
16:14
04/25/17
16:14
Earnings
Mercury Systems reports Q3 adjusted EPS 29c, consensus 16c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

EBSB

Meridian Bancorp

$19.20

0.4 (2.13%)

16:14
04/25/17
04/25
16:14
04/25/17
16:14
Earnings
Breaking Earnings news story on Meridian Bancorp »

Meridian Bancorp reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMP

Compass Minerals

$67.50

-0.1 (-0.15%)

16:14
04/25/17
04/25
16:14
04/25/17
16:14
Hot Stocks
Compass Minerals CFO Linehan to leave company »

Compass Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 04

    May

WYNN

Wynn Resorts

$118.22

2.65 (2.29%)

16:14
04/25/17
04/25
16:14
04/25/17
16:14
Hot Stocks
Wynn Resorts reports Q1 Wynn Palace revenue $475.8M »

Reports Q1 Wynn Palace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MTSI

MACOM

$53.84

-0.17 (-0.31%)

16:14
04/25/17
04/25
16:14
04/25/17
16:14
Earnings
MACOM reports Q2 adjusted EPS 63c, consensus 61c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

UCFC

United Community Financial

$8.70

0.01 (0.12%)

16:13
04/25/17
04/25
16:13
04/25/17
16:13
Earnings
United Community Financial reports Q1 adjusted EPS 9.9c, consensus 11c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

MCRI

Monarch Casino

$29.25

-0.17 (-0.58%)

16:13
04/25/17
04/25
16:13
04/25/17
16:13
Earnings
Monarch Casino reports Q1 diluted EPS 27c, consensus 28c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FISI

Financial Institutions

$34.45

-0.15 (-0.43%)

16:13
04/25/17
04/25
16:13
04/25/17
16:13
Earnings
Financial Institutions reports Q1 EPS 52c, consensus 51c »

Net interest income was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

WYNN

Wynn Resorts

$118.22

2.65 (2.29%)

16:13
04/25/17
04/25
16:13
04/25/17
16:13
Hot Stocks
Wynn Resorts reports Q1 Macau revenues down 3.5% to $587M »

Reports Macau Q1 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NUVA

NuVasive

$76.94

0.59 (0.77%)

16:13
04/25/17
04/25
16:13
04/25/17
16:13
Earnings
NuVasive sees FY17 non-GAAP EPS $2.00, consensus $2.02 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 18

    May

PNRA

Panera Bread

$313.72

-0.35 (-0.11%)

16:12
04/25/17
04/25
16:12
04/25/17
16:12
Earnings
Panera Bread reports Q1 EPS $1.83, consensus $1.84 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

SD

SandRidge Energy

$18.80

0.28 (1.51%)

16:12
04/25/17
04/25
16:12
04/25/17
16:12
Initiation
SandRidge Energy initiated  »

SandRidge Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    May

CMG

Chipotle

$471.33

2.539 (0.54%)

16:12
04/25/17
04/25
16:12
04/25/17
16:12
Earnings
Chipotle backs FY17 SSS view of up in high-single digits »

Backs FY17 restaurant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ILMN

Illumina

$181.50

1.3 (0.72%)

16:11
04/25/17
04/25
16:11
04/25/17
16:11
Earnings
Illumina sees Q2 adjusted EPS 65c-70c, consensus 87c »

Sees Q2 revenue growth of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

GPRO

GoPro

$9.18

0.17 (1.89%)

16:11
04/25/17
04/25
16:11
04/25/17
16:11
Hot Stocks
GoPro says Susan Lyne joins board of directors »

GoPro announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 24

    May

  • 25

    May

CENX

Century Aluminum

$13.62

0.99 (7.84%)

16:11
04/25/17
04/25
16:11
04/25/17
16:11
Earnings
Century Aluminum reports Q1 EPS (5c), consensus (17c) »

Reports adjusted EBITDA1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NUVA

NuVasive

$76.94

0.59 (0.77%)

16:11
04/25/17
04/25
16:11
04/25/17
16:11
Earnings
NuVasive reports Q1 non-GAAP EPS 38c, consensus 38c »

Reports Q1 revenue $250M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 18

    May

CMG

Chipotle

$471.15

2.36 (0.50%)

16:11
04/25/17
04/25
16:11
04/25/17
16:11
Hot Stocks
Chipotle reports Q1 EPS $1.60, consensus $1.27 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

ILMN

Illumina

$181.50

1.3 (0.72%)

16:11
04/25/17
04/25
16:11
04/25/17
16:11
Earnings
Illumina sees FY17 adjusted EPS $3.60-$3.70, consensus $3.64 »

Sees FY17 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

DDR

DDR Corp.

$12.40

0.185 (1.52%)

16:11
04/25/17
04/25
16:11
04/25/17
16:11
Earnings
DDR Corp. reports Q1 EPS (16c), may not compare to consensus 1c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.